Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient.
BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease.
Biotech is playing an increasingly important role in U.S. economic competitiveness and national security, and Utah plays a key role in contributing to the strength of the American biotech ecosystem.
The addition of APEXecm reflects Kolosis’s continued commitment to developing and commercializing best-in-class solutions for the surgical community
Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the U.S.
New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures
For Fabry patients, a potential path to converting 130 clinic visits into one treatment every five years.
New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, building on over 10,000 patient-years of data
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Women-led companies join Springboard’s accelerator to advance innovation across the women’s health landscape.
Deal complements Medtronic’s Neurovascular portfolio, delivering simplicity and access when ‘time is brain’